Xinyu Ke

576 total citations
11 papers, 296 citations indexed

About

Xinyu Ke is a scholar working on Molecular Biology, Surgery and Nephrology. According to data from OpenAlex, Xinyu Ke has authored 11 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 1 paper in Surgery and 1 paper in Nephrology. Recurrent topics in Xinyu Ke's work include RNA Research and Splicing (5 papers), RNA modifications and cancer (4 papers) and RNA regulation and disease (4 papers). Xinyu Ke is often cited by papers focused on RNA Research and Splicing (5 papers), RNA modifications and cancer (4 papers) and RNA regulation and disease (4 papers). Xinyu Ke collaborates with scholars based in Singapore, China and United States. Xinyu Ke's co-authors include Xiangchun Liu, Qi Wu, Zhengguang Li, Yangyang Song, Kai Zhang, Leilei Chen, Ömer An, Henry Yang, Haoqing Shen and Vanessa Hui En Ng and has published in prestigious journals such as Nature Communications, Cancer Research and Oncogene.

In The Last Decade

Xinyu Ke

11 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xinyu Ke Singapore 10 192 76 43 33 22 11 296
Zichang Yang China 11 244 1.3× 160 2.1× 35 0.8× 32 1.0× 56 2.5× 22 384
Deguang Zhang China 11 253 1.3× 196 2.6× 74 1.7× 70 2.1× 22 1.0× 26 472
Han Wu China 10 142 0.7× 89 1.2× 36 0.8× 45 1.4× 15 0.7× 37 294
Fuqiang Pan China 8 127 0.7× 53 0.7× 54 1.3× 39 1.2× 64 2.9× 18 306
Zhengbin Han China 10 215 1.1× 90 1.2× 26 0.6× 47 1.4× 10 0.5× 24 302
Junshu Li China 10 87 0.5× 56 0.7× 17 0.4× 26 0.8× 30 1.4× 15 217
Yamin Gong China 6 200 1.0× 22 0.3× 50 1.2× 39 1.2× 95 4.3× 7 300
Ane Olazagoitia‐Garmendia Spain 9 260 1.4× 196 2.6× 17 0.4× 37 1.1× 18 0.8× 20 395

Countries citing papers authored by Xinyu Ke

Since Specialization
Citations

This map shows the geographic impact of Xinyu Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinyu Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinyu Ke more than expected).

Fields of papers citing papers by Xinyu Ke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinyu Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinyu Ke. The network helps show where Xinyu Ke may publish in the future.

Co-authorship network of co-authors of Xinyu Ke

This figure shows the co-authorship network connecting the top 25 collaborators of Xinyu Ke. A scholar is included among the top collaborators of Xinyu Ke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinyu Ke. Xinyu Ke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Ke, Xinyu, et al.. (2022). Lipid metabolism in tumor-infiltrating T cells: mechanisms and applications. PubMed. 1(3). 211–223. 10 indexed citations
2.
Shen, Haoqing, Ömer An, Xi Ren, et al.. (2022). ADARs act as potent regulators of circular transcriptome in cancer. Nature Communications. 13(1). 1508–1508. 50 indexed citations
3.
Han, Jian, Ömer An, Xi Ren, et al.. (2022). Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer. Nature Communications. 13(1). 1793–1793. 15 indexed citations
4.
Yang, Xueyan, et al.. (2022). SIRT3 deficiency exacerbates early-stage fibrosis after ischaemia-reperfusion-induced AKI. Cellular Signalling. 93. 110284–110284. 28 indexed citations
5.
An, Ömer, Yangyang Song, Xinyu Ke, et al.. (2021). “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Cancer Research. 81(10). 2788–2798. 13 indexed citations
6.
Ke, Xinyu, Ye Chen, Ruby Yu‐Tong Lin, et al.. (2021). MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma. Oncogene. 40(10). 1851–1867. 16 indexed citations
7.
Liu, Xiangchun, et al.. (2021). High-efficiency TiO2/ZnO nanocomposites photocatalysts by sol–gel and hydrothermal methods. Journal of Sol-Gel Science and Technology. 99(1). 92–100. 66 indexed citations
8.
Song, Yangyang, Xinyu Ke, & Leilei Chen. (2020). The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment. Current Medicinal Chemistry. 28(25). 5110–5136. 10 indexed citations
9.
Song, Yangyang, Ömer An, Xi Ren, et al.. (2020). RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. Journal of Hepatology. 74(1). 135–147. 44 indexed citations
10.
Song, Yangyang, Ömer An, Xi Ren, et al.. (2020). RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. 1 indexed citations
11.
Chen, Ye, Liang Xu, Anand Mayakonda, et al.. (2019). Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nature Communications. 10(1). 1353–1353. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026